Literature DB >> 19594606

Symptomatic anastomotic leakage diagnosed after hospital discharge following low anterior resection for rectal cancer.

P Matthiessen1, R Lindgren, O Hallböök, J Rutegård, R Sjödahl.   

Abstract

OBJECTIVE: The aim of this study was to investigate patients with symptomatic anastomotic leakage diagnosed after hospital discharge.
METHOD: Patients (n = 234) undergoing low anterior resection of the rectum for cancer who were included in a prospective multicentre trial (NCT 00636948) and who developed symptomatic anastomotic leakage diagnosed after hospital discharge (late leakage, LL; n = 18) were identified. Patient characteristics, operative details, recovery on postoperative day 5, length of hospital stay, and how the leakage was diagnosed were recorded. A comparison with those who did not develop symptomatic leakage (no leakage, NL; n = 189) was made. The minimum follow up was 24 months.
RESULTS: In the LL patients the median age was 69 years, 61% were female patients, and 6% had stage IV cancer disease. On postoperative day 5, the LL group had a postoperative course similar to the NL group regarding temperature, oral intake and bowel function. The proportion of patients on antibiotic treatment on postoperative day 5, regardless of indication, was 28% in the LL compared with 4% in the NL group (P < 0.001). The median initial hospital stay was 10 days for both groups. When readmission for any reason was added, the hospital stay rose to a median of 21.5 and 13 days in the LL and the NL groups respectively (P < 0.001).
CONCLUSION: Symptomatic anastomotic leakage diagnosed after hospital discharge following low anterior resection of the rectum for cancer is not uncommon and has an immediate clinical postoperative course which may appear uneventful.

Entities:  

Mesh:

Year:  2009        PMID: 19594606     DOI: 10.1111/j.1463-1318.2009.01938.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  7 in total

1.  Circular anastomotic experimental fibrin sealant protection in deep colorectal anastomosis in pigs in a randomized 9-day survival study.

Authors:  F A Wenger; E Szucsik; B F Hoinoiu; A M Cimpean; M Ionac; M Raica
Journal:  Int J Colorectal Dis       Date:  2015-05-27       Impact factor: 2.571

2.  A modular magnetic anastomotic device for minimally invasive digestive anastomosis: proof of concept and preliminary data in the pig model.

Authors:  Michele Diana; Didier Mutter; Véronique Lindner; Michel Vix; Hyunsoo Chung; Nicolas Demartines; Jacques Marescaux
Journal:  Surg Endosc       Date:  2014-01-03       Impact factor: 4.584

3.  Outcomes of asymptomatic anastomotic leaks found on routine postoperative water-soluble enema following anterior resection for cancer.

Authors:  S Killeen; P Souroullas; H Ho Tin; I A Hunter; H O'Grady; J Gunn; J E Hartley
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

4.  Very Early Colorectal Anastomotic Leakage within 5 Post-operative Days: a More Severe Subtype Needs Relaparatomy.

Authors:  Yi-Wei Li; Peng Lian; Ben Huang; Hong-Tu Zheng; Ming-He Wang; Wei-Lie Gu; Xin-Xiang Li; Ye Xu; San-Jun Cai
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

5.  Consensus on the definition of colorectal anastomotic leakage: A modified Delphi study.

Authors:  Claire Pm van Helsdingen; Audrey Chm Jongen; Wouter J de Jonge; Nicole D Bouvy; Joep Pm Derikx
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

6.  Risk Factors of Anastomotic Leakage and Long-Term Survival After Colorectal Surgery.

Authors:  Jong Seob Park; Jung Wook Huh; Yoon Ah Park; Yong Beom Cho; Seong Hyeon Yun; Hee Cheol Kim; Woo Yong Lee
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

7.  Influence of concurrent capecitabine based chemoradiotherapy with bevacizumab on the survival rate, late toxicity and health-related quality of life in locally advanced rectal cancer: a prospective phase II CRAB trial.

Authors:  Vaneja Velenik; Vesna Zadnik; Mirko Omejc; Jan Grosek; Mojca Tuta
Journal:  Radiol Oncol       Date:  2020-08-01       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.